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Circulating tumor cells (CTCs) must be phenotypically and genetically characterized before they can be
utilized in clinical applications. Here, we present the first protocol for the detection of miRNAs in CTCs
using in situ hybridization (ISH) combined with immunomagnetic selection based on cytokeratin (CK)
expression and immunocytochemistry. Locked-Nucleic Acid (LNA) probes associated with an
enzyme-labeled fluorescence (ELF) signal amplification approach were used to detect miRNA-21 in CTCs.
This protocol was optimized using both epithelial tumor (MDA-MB468) and epithelial non-tumor
(MCF-10A) cell lines, and miRNA-21 was selected as the target miRNA because of its known role as an
onco-miRNA. Hematopoietic cells do not express miRNA-21; thus, miRNA-21 is an ideal marker for
detecting CTCs. Peripheral blood samples were taken from 25 cancer patients and these samples were
analyzed using our developed protocol. Of the 25 samples, 11 contained CTCs. For all 11 CTC-positive
samples, the isolated CTCs expressed both CK and miRNA-21. Finally, the protocol was applied to monitor
miRNA-21 expression in epithelial to mesenchymal transition (EMT)-induced MCF-7 cells, an epithelial
tumor cell line. CK expression was lost in these cells, whereas miRNA-21 was still expressed, suggesting that
miRNA-21 might be a good marker for detecting CTCs with an EMT phenotype.
M
etastasis is responsible for the vast majority of cancer-related deaths1. During this process, circulating
tumor cells (CTCs) are generated and shed from the primary tumor, colonize distant organs and lead to
overt metastatic disease. In the past decade, a growing interest in CTCs has developed among oncology
researchers and clinicians because of the potential of CTCs as prognostic elements of cancer2,3. Despite significant
progress in understanding and detecting CTCs, the sensitivity of most assays is low, mainly due to the fact that
only a few epithelial biomarkers are used to identify and isolate CTCs from whole blood. EpCAM and cytoker-
atins (CKs) are the two main epithelial biomarkers that are used in most of the devices that have been utilized to
date4–6. Among these devices, CellSearch and GILUPI, which have been approved as medical devices by the FDA
and the EU, respectively, can detect only EpCAM in circulating cells in the blood7,8.
However, recent evidence has demonstrated that a subset of CTCs may lack EpCAM and CK expression and
instead exhibit features of epithelial to mesenchymal transition (EMT)9. Additionally, the use of epithelial
biomarkers might lead to the identification of epithelial cells within hematopoietic cell populations that are
not derived from tumors but are instead from other epithelial tissues. Accordingly, the development of novel
detection platforms should be accompanied by the identification of novel and specific CTC biomarkers that
enhance the detection and molecular characterization abilities of these platforms10.
MicroRNAs (miRNAs) are small non-coding RNAs that play a key role in the post-transcriptional regulation
of mRNA. The relationships between variations in miRNA expression and different pathologies, including
different types of cancer11, have been described in many reports. miRNAs also circulate within bodily fluids,
including peripheral blood and urine, and many studies have reported a correlation between the levels of specific
circulating miRNAs and different pathologies, especially cancer12. Therefore, miRNAs have been proposed as
ideal biomarkers for the development of diagnostic and prognostic liquid biopsy assays. However, the technical
difficulties associated with performing robust and comparable profiling of circulating miRNAs across different
platforms as well as inter-individual variability, a lack of common internal normalization controls and the unclear
functional roles of these miRNAs have impeded the development of an approved clinical diagnostic assay13.
To date, there have been many efforts to correlate circulating miRNAs with the number of CTCs14. Moreover,
in 2011, Sieuwerts profiled miRNAs from the lysates of blood fractions containing CTCs. However, it may be
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issue of leukocyte contamination. Therefore, there is a clear need for
an efficient and sensitive method for the detection of miRNA within
CTCs.
The aim of this study was to develop protocols to detect CTCs in
patient blood samples via miRNA in situ hybridization in CTC
(MishCTC) that are combined with simultaneous immunocyto-
chemistry protocols for cell phenotyping. To our knowledge, this is
the first report of a protocol that can be used to identify miRNAs in
CTCs using in situ hybridization techniques.
Results
Integration of LNA-based miRNA-ISH techniques and CTC de-
tection protocols. To detect miRNAs in CTCs, we integrated
ISH protocols for detecting miRNAs in single cells with the
methodological steps necessary to isolate and identify CTCs from
patient blood. The initial experiments were performed using a breast
epithelial tumor cell line as a model. Briefly, cells were collected from
plates and placed on slides via CytoSpin centrifugation. The cells
were then treated with EDC16 to covalently immobilize the
miRNAs in the cytoplasm. Detection was performed via an
enzyme-labeled fluorescence (ELF) signal amplification approach17
using miRCURY technology, which is based on LNA probes18. This
technology uses labeled LNA probes, which hybridize to fully
complementary miRNA sequences with high affinity. These tags
can then be identified via antibodies that are labeled with enzymes
that convert fluorogenic enzymatic substrates into fluorescent
products. Herein, digoxin (DIG) and a sheep anti-DIG antibody
labeled with alkaline phosphatase were used as partners, and
FastRed TR was used as a fluorogenic substrate. Upon exposure to
alkaline phosphatase enzymatic activity, the FastRed TR substrate
produces an insoluble product that can be detected by fluorescence
microscopy (Fig. 1).
The breast epithelial tumor cell line MDA-MB468 was used as a
model in which to detect miRNA-200, miRNA-21 and U6 in situ by
fluorescence microscopy. In addition to the RNAs, nuclei and cyto-
keratins were also stained with DAPI and FITC-labeled anti-cytoker-
atin antibodies, respectively (SI Fig. 1 shows the fluorescence images
that were obtained using this methodology). The rounded cell
morphologies and miRNA distributions are concordant with
CytoSpin treatments and with LNA-based ELF detection, respect-
ively19. This protocol, which successfully detected RNA via ELF sig-
nal amplification in cells that were placed on slides via CytoSpin, was
then applied for further experiments.
Detection of miRNA-21 in blood samples from a healthy volun-
teer that were spiked with MDA-MB468 cells. The very low number
of CTCs in blood compared to the number of the hematopoietic cells
is one of the most challenging aspects for any technology focused on
molecular characterization. To optimize the methodological steps
that are required to isolate CTCs from blood via positive selec-
tion of cells with an epithelial phenotype and subsequently detect
miRNAs, we spiked blood samples from 15 healthy volunteers
with 100 epithelial cells (MDA-MB468) each. The isolation of
cytokeratin-positive cells and their further phenotypic charac-
terization were based on a protocol that was previously established
by our group6 with minor modifications (see Methods, Fig. 1). After
dispensing the cytokeratin-positive cell fractions onto slides via
CytoSpin centrifugation, we followed the same protocol described
above to identify miRNA-21. We selected miRNA-21 for our in situ
experiments because it is one of the most important miRNAs related
to cancer development20. Moreover, the selected miRNA had an
important required feature: it was expressed in tumor cells but not
in hematopoietic cells. Thus, CTCs and leukocytes can be easily
differentiated using miRNA-21 as a marker. In addition, it is
possible that miRNA-21 could be used to differentiate CTCs from
normal epithelial cells, as its expression levels in these cells might be
different. We isolated an average of 79% of the total spiked cells and
found that in every sample, every cell that was cytokeratin-positive
Figure 1 | Schematic illustration of the MishCTC method for simultaneous miRNA and CK detection via immunocytochemistry. (A) Recovery of
peripheral blood into an EDTA tube; (B) blood transfer into a density-gradient centrifuge tube; (C) centrifugation at 700 3 g for 30 min; (D) recovery of
the interphase layer, which contains mononuclear and tumor cells, and immunomagnetic labeling with magnetic microbeads conjugated to an
anti-CK antibody; (E) magnetic cell separation using a MiniMACS separator and a pre-filled separation column; (F) elution of retained cells; (G)
application of the cells to a polylysine glass slide using CytoSpin centrifugation; and (H) MishCTC detection of miRNA and CK. Mr. Juan M. Agudo
helped to prepare this artwork.
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also expressed miRNA-21 without exception (SI Table 1). Fig. 2a
shows images from a spiking experiment in which a single MDA-
MB468 cell was detected amongst the leukocyte population. miRNA-
21 can be clearly identified in epithelial cells, whereas it is not
detected in leukocytes; thus, it fulfills one of the most important
requirements for this assay. These data demonstrate that miRNA-
21 expression is a specific biomarker for epithelial cells that does not
appear in hematopoietic lineages.
Quantification of miRNA-21 in MDA-MB468 and MCF-10A cell lines
by qRT-PCR. Before proceeding with the analysis of blood samples
from cancer patients, we investigated whether miRNA-21 was ex-
pressed equally in tumor and non-tumor epithelial cells. We therefore
performed both in situ hybridization of miRNA-21 according to
previously established protocols and a miRNA-21 expression analysis
by qRT-PCR in a breast cancer cell line (MDA-MB468) and a normal
breast cell line (MCF-10A). The fluorescence intensities per cell and
ddCT values from both of the cell lines confirmed that miRNA-21 is
overexpressed in epithelial tumor cells compared with non-tumor cells
(see Methods, SI Fig. 2 and SI Fig. 3). These results confirm that
miRNA-21 is a valid biomarker that can be used to differentiate
CTCs from leukocytes and tumor from non-tumor epithelial cells.
Detection of miRNA-21 in CTCs from blood samples of cancer
patients. To evaluate the potential implementation of this method as
a diagnostic tool in patient blood samples, we used peripheral blood
samples obtained from 25 patients with metastatic cancer who
provided informed consent (SI Table 2). All the samples, including
those from healthy donors, were treated and analyzed as described
above. CTCs were detected in 11 patients, and in every case, CTCs
were identified concomitantly by CK and miRNA-21 expression
(Fig. 2b and SI Table 2). All the samples from healthy donors were
negative for both CK and miRNA-21 expression. Finally, to confirm
that miRNA-21 is expressed differently in circulating tumor and
non-tumor epithelial cells, a blood sample from a cancer-free
patient who recently underwent a nephrectomy was used as a
source of circulating non-tumor epithelial cells. Fig. 2b shows
microscopy images of that sample following our MishCTC
protocol. In this case, the epithelial cells did not show miRNA-21
expression, although they maintained an epithelial cytokeratin
phenotype.
Detection of miRNA-21 in EMT-induced MCF-7 cells. We used
the MishCTC protocol to investigate miRNA-21 expression in the
EMT-induced MCF-7 cell line, an epithelial tumor cell line, as a
model of the heterogeneity of CTCs that was recently reported by
our group21 Kubo et al.22 and Paramio et al.23 reported that miRNA-
21 is induced in epithelial cells undergoing EMT, and standard
markers, such as cytokeratin, are lost in these cells. We therefore
investigated whether our method could be used to detect
heterogeneous epithelial cell lines that had lost epithelial
biomarkers, such as cytokeratin, but still maintained expression of
miRNA-21 as reported by Kubo et al.22 and Paramio et al.23. MCF7
cells were plated in 96-well plates and induced with TGF-b as
previously reported by our group21. SI Fig. 4 presents miRNA-21
and CK expression in both MCF-7 and TGF-b-induced MCF-7
cell lines that were labeled using the MishCTC protocol.
Unmodified MCF-7 cell lines expressed miRNA-21 in a
heterogeneous manner within the same cell culture, and this
heterogeneity was not observed previously in MDA-MBA468 cells.
In the TGF-b-induced MCF-7 cell line, as expected, there was a
population of cells that had lost CK expression but maintained
Figure 2 | Image galleries obtained with the MishCTC method. (a) CK and miRNA-21 expression in an MDA-MB468 cell that was spiked into a blood
sample from a healthy volunteer. Detection of cytokeratin-positive (CK1) cells (green channel), miRNA-21-positive cells (red channel) and nuclei (blue
channel). Epithelial cells were identified in a leukocyte population that did not express miRNA-21. (b) CK and miRNA-21 expression in a CTC from a
patient with metastatic lung cancer. All the CTCs that were found within this set of patients were both CK- and miRNA-positive (upper panel). CK
expression in a circulating epithelial cell from a cancer-free patient undergoing a nephrectomy. CK protein expression (green) was detected by
immunofluorescence, but miRNA-21 could not be detected by in situ hybridization (lower panel).
www.nature.com/scientificreports
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miRNA-21 expression, generating cells that were CK-negative and
miRNA-21-positive.
Discussion
We present the first protocol for detecting miRNAs in CTCs using an
ISH technique called MishCTC. This protocol is compatible with
immunocytochemical detection of protein markers and uses LNA-
based probes with an ELF signal amplification approach. The
MishCTC protocol was generated via the integration of ISH tech-
niques with standard protocols for CTC enrichment from blood
samples based on immunomagnetic positive selection of epithelial
cells. Using this protocol, the expression of miRNA-21, an onco-
miRNA, was determined. A total of 25 patients were recruited, 11
of which presented CTCs with CK expression. The expression of
miRNA-21 was restricted to epithelial tumor cells in the peripheral
blood of these patients and was absent from the leukocytes. One of
the challenges of working with CTCs is that contamination with
hematopoietic cells is always present, even after enrichment.
However, miRNA-21 is not expressed in leukocytes, which is a major
advantage. This protocol was also used to analyze EMT-induced cell
lines and was capable of identifying cells that were negative for epi-
thelial markers (CK-) and positive for miRNA-21 expression.
Currently, we are recruiting a larger cohort of cancer patients to
investigate CTC heterogeneity based on miRNA expression using
the MishCTC protocol.
The detection and characterization of CTCs is complex, and many
groups studying the molecular and phenotypic characteristics of
CTCs are aiming to better understand metastatic processes. Some
researchers have examined the correlation between the expression of
miRNA (as detected in the tissue or serum) with the presence or
absence of CTCs. However, the detection of miRNA in CTCs via
in situ methods has not been previously reported. These protocols
can also be used to better understand the molecular mechanisms that
are associated with dissemination and metastatic processes.
This report is the first proof of concept for MishCTC, which will be
used to analyze multiple miRNAs in CTCs. MishCTC protocol is
thus a potential tool that can be used to monitor cancer patients and
determine the efficacy of their treatments.
Methods
All the experiments were performed in accordance with the relevant guidelines and
regulations.
Cell culture. Breast cancer cell lines were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). The MDA-MB468 tumor cells were
maintained in DMEM culture medium (Gibco, Paisley, UK) that was supplemented
with 10% fetal bovine serum (Gibco), 100 U ml21 penicillin and 100 ng ml21
streptomycin at 37uC in a humidified incubator with 5% CO2. MCF-10A non-tumor
cells were maintained in serum-free mammalian epithelial growth medium (MEGM)
(CloneticsH Lonza, South Plainfield, NJ, USA) with 100 ng mL21 cholera toxin
(Sigma-Aldrich, Saint Louise, MO, USA).
Preparation of breast cancer cell lines via CytoSpin for the simultaneous detection
of cytokeratins and miRNAs. One million cells were seeded in a 75-cm2 treated flask
(NUNCTM, Roskilde, Denmark) in their corresponding cell culture media. After
incubation for 72 h, each well was washed with PBS, and the cells were trypsinized
with 0.05% trypsin in 13 PBS for 15 min, neutralized with soybean trypsin inhibitor
(0.1% trypsin inhibitor in 13 PBS) and resuspended in PBS (pH 7.4). The cell
suspensions were then permeabilized with 10% MACS Cell Perm Solution (Miltenyi
Biotec, Bergisch Gladbach, Germany) for 5 min and fixed with 10% MACS Cell Fix
Solution (Miltenyi Biotec)or 30 min followed by washing three times with 13 PBS
(5 min each wash). The cell pellets were resuspended in 13 PBS and spun down onto
polylysine-coated glass slides (Sigma-Aldrich, Gillingham, UK) using a
cytocentrifuge (Hettich, Germany) at 1,500 rpm for 10 min. The slides were air-dried
overnight at room temperature and stored at 4uC. The dried slides containing cells
that were immobilized by CytoSpin were rehydrated with 13 TBS buffer for 5 min
and treated twice (5 min each treatment) with 100 ml of a 130 mM aqueous solution
of 1-methylimidazole (AppliChem, Darmstadt, Germany). The areas of interest were
then marked with a hydrophobic pen (Dako, Glostrup, Denmark). Subsequently,
100 ml of a 160 mM aqueous solution of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (Sigma-Aldrich, UK) was added, and the
slides were placed in a humidity chamber (ThermoBrite system, Abbot Molecular,
Des Plaines, IL, USA) for 1 h. Then, the slides were washed twice for 5 min with 13
PBS before incubation in a hybridization chamber for 30 min with 100 ml of
Proteinase QS solution (158000 dilution in 13 PBS) (Affymetrix, Santa Clara, CA,
USA). The slides were then washed twice for 5 min with 13 PBS before being
dehydrated with increasing ethanol concentrations (70%, 96% and 99.5%; 1 min at
each concentration) (Sigma–Aldrich, UK).
LNA-based detection probes. Locked nucleic acid (LNA)-based oligonucleotides for
the detection of miRNA-21, miRNA-200a and U6 snRNA were purchased from
Exiqon (Vedbæk, Denmark) as miRCURY LNATM miRNA kits. These
oligonucleotides are 20-mer oligonucleotides that are labeled at both the 59 and 39
ends with digoxin (DIG).
Simultaneous detection of cytokeratins and miRNAs by fluorescent
immunocytochemistry and ISH techniques (MishCTC). The expression of
miRNA-21, miRNA-200a and U6 snRNA was determined using miRCURY LNATM
miRNA kits (see above). Each probe was independently analyzed. After dehydration,
the slides were air-dried and incubated with 40 ml of a diluted solution (15600) of the
corresponding LNA miRNA probe, which was pre-denatured by heating at 90uC for
4 min in 1 3 ISH buffer (Exiqon) and hybridized at 58uC in a humidified chamber for
1 h after sealing the samples with fixogum. Following hybridization and the removal
of the fixogum, the slides were washed with 53, 13 and 0.23 SSC (5 min each wash)
at 56uC. The samples were then incubated for 15 min in a blocking solution (0.1%
Tween, 2% sheep serum and 1% BSA in 13 PBS) followed by incubation for 15 min in
a solution containing both a FITC-anti-cytokeratin antibody (clone: CK3-6H5;
Miltenyi Biotec) and an anti-DIG alkaline phosphatase antibody (Roche Diagnostics,
Germany). After incubation with both of the antibodies, the samples were washed
with 13 PBS for 5 min. Enzyme-labeled fluorescence (ELF) signal amplification was
achieved by applying SIGMAFASTTM FastRed TR/Naphthol (Sigma-Aldrich, UK),
diluted in Tris-HCl buffer according to the manufacturer’s recommendations, as a
substrate for alkaline phosphatase. Finally, VECTASHIELD mounting medium with
DAPI (Vector Labs, Burlingame, CA, USA) was used to mount the slides.
Spiking experiments. Spiking experiments were performed in triplicate by
dispensing 100 MDA-MB 468 cells into 10-ml venous blood samples that were
collected from 20 healthy volunteers in 10-ml EDTA tubes (BD, Franklin Lakes, NJ,
USA). The samples were processed by density gradient centrifugation for 45 min at
400 rpm. HistopaqueH-1119 (Sigma-Aldrich, UK) was used to isolate the
hematopoietic cell fractions, which also contain epithelial cells. The hematopoietic
fractions were then incubated for 30 min with magnetic microbeads that were labeled
with a multi-cytokeratin-specific antibody (CK3-11D5) (Miltenyi Biotec) that
recognizes cytoplasmic cytokeratins 7, 8, 18 and 19. The magnetically enriched cell
fractions were then passed through MACS Cell Separation magnetic columns
(Miltenyi Biotec) that were supported by a MiniMACS separator (Miltenyi Biotec)
and washed three times with dilution buffer (Miltenyi Biotec). The magnetic columns
were then detached from the MiniMACS separator support, and the cytokeratin-
positive cells were eluted from the column after adding dilution buffer and applying
pressure. The cytokeratin-positive-enriched cell fractions were spun down onto
polylysine-coated glass slides. Then, previously described protocols were utilized for
the simultaneous detection of cytokeratins and miRNAs. The recovery rates of tumor
cells spiked into normal blood at low levels ranged from 60% to 75%.
Analysis of CTCs from patient samples. A total of 25 patients with metastatic cancer
from the Breast Cancer Unit of the University Hospital of Granada were enrolled in
the study from December 2013 to January 2014. The inclusion criteria were the
histological diagnosis of lung cancer (LC), prostate cancer (PC), colon cancer (CC),
urothelial cancer (UC), breast cancer (BC), gastric cancer (GC), ovarian cancer (OC)
or melanoma (MC) and the availability of tissue for biomarker studies (SI Table 2).
This translational study was approved by the Independent Ethics Committee of San
Cecilio Hospital (Granada, Spain). Following the approval of the study by The Ethics
Committee, eligible patients were selected and informed written consents were
provided.
As negative controls, 5 blood samples from healthy volunteers without evidence of
epithelial malignancy were examined. Peripheral blood was drawn from the middle of
the vein puncture, and the first 3 ml of blood was discarded to avoid contamination of
the sample with non-tumor epithelial cells from the skin. Blood samples were col-
lected in EDTA tubes and transported immediately to the laboratory. Then, the
protocols described in the ‘‘Spiking experiments’’ section were performed.
RNA extraction, reverse-transcription and qRT-PCR. The expression of miRNA-
21 and miRNA-200a was analyzed in breast cancer cell lines. The cells (13103) were
plated in a 75-cm2 treated flask (NUNCTM, Roskilde, Denmark) and grown in culture
medium for 72 h. Subsequently, the cells were treated for 3 min with trypsin solution
(Sigma Aldrich, US), and 5 ml of medium was added to inhibit the tryptic activity,
which may damage the cells. Next, the cells were centrifuged at 200 3 g for 5 min,
collected in 15-ml tubes, and washed once with 13 PBS prior to the addition of 0.5 ml
of miRNA Extraction Kit Lysis Mixture (Omega Bio-Tek, Norcross, GA, USA) per
tube. The tubes were then incubated for 5 min at room temperature. Then, 250 ml of
XD binding buffer was added, and the tubes were incubated on ice for 10 min. After
this incubation period, the solution was added to a Hi-BindH X-press column and
centrifuged for 1 min at 13,000 3 g. Then, 1.2 volumes of ethanol were added to the
filtrate, which was transferred to a Hi-BindH MicroRNA column and centrifuged
www.nature.com/scientificreports
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again at 13,000 3 g for 1 min. The filtrate was then discarded, and the miRNAs were
retrieved from the columns via the addition of 500 ml of RNA wash buffer. The
miRNA that was retrieved from the columns was mixed with 5 ml of extracted miRNA
and incubated with 1 ml of poly(A), 2 ml of tailing buffer and 2 ml of nuclease-free
water (Quanta BioSciences, Gaithersburg, MD, USA). This mixture was incubated at
37uC for 60 min, followed by a 5-min incubation at 70uC. For RT-PCR, a reaction mix
was prepared by mixing 25 ml of PerfeCTa SYBR Green Supermix (ROX) with
primers (200 nM) and template in a final volume of 50 ml. RT-PCR was performed in
triplicate in 96-well plates using a Real-Time PCR System (Applied BiosystemsH 7500
Real-Time PCR System, Drive Foster City, CA, USA). After an initial denaturation at
95uC for 2 min, 40 cycles of denaturation at 95uC, annealing at 60uC for 1 min, and
extension at 70uC for 1 min were carried out.
TGF-b2induced EMT cell lines. These methods were previously reported by our
group21.
Confocal microscopy. Confocal images were obtained using a Zeiss LSM 710
confocal/multiphoton laser scanning microscope that was equipped with an Argon/2
laser (458 nm, 477 nm, 488 nm, and 514 nm) and a Titanium Sapphire laser
(750 nm). The cells were viewed with a 363 (NA1.2) apochromatic water objective,
and images of different fields were obtained. The microscope was set up to obtain
multichannel images, and the excitation and emission filter sets were configured
individually to ensure no fluorescence bleed-through between the channels. An argon
laser was used to visualize FITC with excitation at 488 nm and FastRed with
excitation at 543 nm. The appropriate emission filters were used for each
fluorophore. FITC was used to label CK, and FastRed/Naphthol was used to label each
analyzed miRNA. Zen 2009 light edition software (Carl Zeiss MicroImaging GmbH)
was used for image processing and for control of the microscope, the scanning
module, and the laser module.
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